Selected article for: "clinical evidence and real world"
Author: Jones, Madison E.; Kohn, Alison H.; Pourali, Sarah P.; Rajkumar, Jeffrey R.; Gutierrez, Yasmin; Yim, Rebecca M.; Armstrong, April W.
Title: The Use of Biologics During the COVID-19 Pandemic
  • Cord-id: 1iyeq618
  • Document date: 2021_6_1
    • ID: 1iyeq618
    Snippet: During the COVID-19 pandemic, there has been considerable discussion regarding the use of biologics in patients with inflammatory skin conditions, such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. This article discusses clinical trial data, real world evidence, and guidelines and recommendations for biologics that inhibit TNF, IL-12/23, IL-17, IL-23, and IL-4/13 during the COVID-19 pandemic. Across these inflammatory skin conditions, existing data generally suggest that biologi
    Document: During the COVID-19 pandemic, there has been considerable discussion regarding the use of biologics in patients with inflammatory skin conditions, such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. This article discusses clinical trial data, real world evidence, and guidelines and recommendations for biologics that inhibit TNF, IL-12/23, IL-17, IL-23, and IL-4/13 during the COVID-19 pandemic. Across these inflammatory skin conditions, existing data generally suggest that biologics do not appear to increase the risk of COVID-19 infection nor worsen COVID-19 outcomes. The impact of biologics on COVID-19 is an area of active exploration.

    Search related documents:
    Co phrase search for related documents
    • active infection and ad management: 1
    • active infection and lung damage: 1, 2, 3, 4, 5, 6
    • active infection patient and lung damage: 1
    • ad atopic dermatitis and ad management: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • ad atopic dermatitis and ad patient: 1, 2, 3, 4, 5, 6
    • ad atopic dermatitis and lung damage: 1, 2
    • ad management and ad patient: 1